Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Lamivudine + Zidovudine). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended dosage for adults and adolescents: In HIV-1-infected adults and adolescents weighing 30 kg or more, the usual dose is 1 tablet (containing 150 mg lamivudine and 300 mg zidovudine) taken by mouth twice daily. Recommended dosage for pediatric patients: For children weighing 30 kg or more who are able to take a solid oral dosage form, the usual dose is also 1 tablet taken by mouth twice daily on an empty stomach. Before this medicine is prescribed, the child's ability to swallow tablets should be assessed; if a child cannot reliably swallow a tablet, a liquid oral formulation should be used instead. Not recommended due to lack of dosage adjustment: because this is a fixed-dose combination tablet that cannot be adjusted, it is not recommended for pediatric patients weighing less than 30 kg, patients with creatinine clearance below 50 mL per minute, patients with hepatic impairment, or patients experiencing dose-limiting adverse reactions. For these groups, the individual components are available separately in liquid and solid oral formulations.
Side Effects
Side effects of this medicine More common: chills, fever, pale skin, sore throat, unusual tiredness or weakness, and headache. Less common: abdominal pain; a burning, tingling, or numb sensation or pain in the hands, arms, feet, or legs; muscle tenderness and weakness; nausea; skin rash; vomiting; and yellowing of the eyes or skin. Coughing, reduced appetite, diarrhea, dizziness, and trouble sleeping may also occur.
Cautions & Contraindications
Warnings & Precautions
Patients with HIV and Hepatitis B virus Coinfection: Safety and efficacy of Lamivudine have not been established for treatment of chronic hepatitis B in patients dually infected with HIV and HBV. Emergence of hepatitis B virus variants associated with resistance to Lamivudine has also been reported in HIV-infected patients who have received Lamivuuine-containing antiretroviral regimens in the presence of concurrent infection with Hepatitis B virus. Post-treatment exacerbations of hepatitis have also been reported.Patients with Impaired Renal Function: Reduction of the dosages of Lamivudine and Zidovudine is recommended for patients with impaired renal function. Patients with creatinine clearance <50 ml/min should not receive Avudin tablet.Fat Redistribution: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breastenlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.
Contraindications
Contraindicated in patients with a known history of clinically significant hypersensitivity to any of its ingredients. Because Lamivudine doses need to be reduced in patients weighing less than 50 kg (110 lb), the fixed-dose Lamivudine & Zidovudine combination is not suitable for use in low-body-weight patients.